PARIS (AFP) – A new compound, tested so far on rats, shows promise in restoring functions lost by paralysing injury to the spinal cord, a study said on Wednesday.
Called intracellular sigma peptide (ISP), the drug helped lab animals with severe spinal injury recover the ability to urinate or move, or both, it said.
More work is needed, but the scientists behind ISP said the results boosted hopes for a future therapy for humans. “We’re very excited at the possibility that millions of people could, one day, regain movements lost during spinal cord injuries,” said Jerry Silver, a professor of neurosciences at Case Western Reserve University in Cleveland, Ohio.
Published in the journal Nature, the research looked at ways of overcoming scarring when nerve fibres in the spinal cord are damaged and signals from the brain no longer reach muscles below the injury site.
Nerve fibres try to cross the injury site and reconnect with other fibres, but become trapped at the scar site by sticky proteins called proteoglycans.
ISP is designed to act on the receptor on the surface of the nerve cells. Like a switch, it turns off a response to the proteoglycans that causes the blockage.
In the experiment, 26 rats were given severe spinal cord injuries followed by daily injections of the treatment for seven weeks.
Twenty-one of the 26 regained one or more of three functions – the ability to walk, to balance and to control when and how much they urinated.
Some animals regained all three, others one or two, and five none. Why a specific animal regained a specific function remains unclear.
ISP drug did not cause nerve fibres that control movement to cross the scar area and reconnect with those on the other side.